Can I Take Creatine with Low-Dose Naltrexone?

The direct answer

There is no known pharmacokinetic or pharmacodynamic interaction between creatine monohydrate and low-dose naltrexone. Naltrexone is metabolized hepatically (largely to 6-beta-naltrexol) and does not meaningfully affect cytochrome P450 enzymes at therapeutic doses, according to its FDA label. Creatine is taken up by muscle through a dedicated transporter and broken down non-enzymatically into creatinine, with no hepatic enzyme involved. The two substances do not compete for the same receptors, transporters, or metabolic pathways, so a direct drug interaction is not pharmacologically plausible based on how each is handled by the body.

The genuine concern for someone taking both is analytic, not pharmacological. Creatine supplementation is well established in the sports nutrition literature to raise serum creatinine without necessarily reducing actual glomerular filtration. Because LDN prescribers commonly order baseline and follow-up renal panels (a reasonable general safety practice, not a requirement specific to LDN), a creatine user's creatinine can look elevated on paper even when kidney function is normal. Flagging creatine use to your prescriber before labs are drawn, and asking whether cystatin C should be added, is the practical step that prevents a false alarm from affecting your care.

What's established, what's plausible, and what isn't known

Established:

• Naltrexone's approved indications, dosing, and boxed warning for hepatotoxicity are described in its FDA label. The boxed warning is tied to studies at 300 mg/day (an obesity-trial dose), which is six times the approved 50 mg dose and far higher than typical LDN doses of 1.5 to 4.5 mg.
• Creatine monohydrate is metabolized outside the liver, primarily taken up in skeletal muscle, and converted to creatinine as a metabolic byproduct.
• Serum creatinine is a widely used but imperfect surrogate for kidney function, and clinical nephrology guidance recognizes that conditions altering muscle creatine turnover (including supplementation) can make creatinine-based eGFR misleading. Cystatin C is one alternative marker used in that situation.

Plausible but not established from the sources reviewed here:

• A specific numeric estimate of how much serum creatinine rises with typical creatine dosing (commonly cited figures in sports nutrition circles fall in a range, but a precise percentage should be checked against the current primary literature rather than treated as fixed).
• Whether LDN and creatine have any overlapping, complementary anti-inflammatory effect. Both are proposed to influence inflammatory signaling through different mechanisms (LDN via opioid receptor and possible TLR4 modulation, creatine via cellular energetics), but no clinical trial has tested the combination directly, and neither mechanism has been proven to translate into a meaningful added benefit or risk when combined.

Not established:

• Any direct pharmacokinetic or pharmacodynamic interaction between creatine and naltrexone at any dose.
• Long-term outcomes of combined creatine and LDN use specifically; the two have been studied separately, not together.
• Safety of creatine supplementation in people with pre-existing significant kidney disease; general population data on healthy adults do not automatically extend to this group.

Why LDN monitoring makes this relevant

Naltrexone at the FDA-approved 50 mg dose carries a boxed warning for hepatocellular injury, based on data from higher-dose obesity trials. LDN prescribers, working off-label at 1.5 to 4.5 mg, commonly still order baseline liver and kidney panels as routine safety practice, even though the pharmacology and dose are quite different from the labeled indication. If a creatine user's creatinine comes back elevated on one of these panels, a prescriber unfamiliar with the creatine-creatinine confound may pause LDN, order additional imaging, or reduce a dose that had otherwise been working well. That is a real and avoidable disruption to care, even though it has nothing to do with an actual drug interaction.

Why the two don't share a metabolic pathway

Naltrexone is absorbed orally and undergoes extensive first-pass hepatic metabolism, converting to the active metabolite 6-beta-naltrexol. Its label states it does not significantly inhibit or induce major CYP enzymes at therapeutic doses.

Creatine is absorbed through an intestinal and cellular creatine transporter, stored in muscle as phosphocreatine, and degraded non-enzymatically to creatinine, which the kidneys filter and excrete. No hepatic enzyme system is involved in that conversion.

Because one substance is processed hepatically and the other moves through a muscle-and-renal pathway with no shared enzyme, transporter, or receptor, a pharmacokinetic interaction is not mechanistically expected. This absence of a shared pathway is consistent with the lack of any reported interaction in the literature reviewed for this page, though the absence of reported cases is not the same as a formal interaction study having been done, and none appears to exist.

The creatinine monitoring problem, in practice

Serum creatinine is a surrogate marker, not a direct measurement of kidney function. Clinical nephrology guidance recognizes that in people with altered muscle creatine turnover, including supplement users, creatinine-based estimates of kidney function can be inaccurate, and recommends cystatin C, alone or combined with creatinine, in that setting.

Evidence-status interaction assessment: creatine + low-dose naltrexone

What to verify with your clinician or pharmacist before relying on this table: the current package label for your specific naltrexone product, your own baseline kidney function, whether cystatin C is available and appropriate at your lab, and whether any other medications or supplements you take (including NSAIDs or other agents affecting kidney function) change this picture.

Hepatotoxicity: keeping the boxed warning in proportion

The FDA boxed warning for naltrexone describes liver injury observed at 300 mg/day in obesity trials, a dose far above the approved 50 mg tablet and dramatically above typical LDN doses of 1.5 to 4.5 mg. This does not mean LDN carries no hepatic risk at all, but the dose-response relationship matters: the data behind the warning were generated at doses many times higher than what LDN prescribers use. Claims about hepatotoxicity rates specifically at LDN doses vary across the LDN-focused literature, and a precise number should be checked against the current primary studies rather than repeated as settled.

Creatine at recommended doses is not established to be hepatotoxic in healthy adults, and standard sports nutrition sources describe no consistent liver enzyme elevation from typical use. There is no basis in the current evidence for expecting creatine to add to whatever hepatic risk LDN carries. Routine liver panel monitoring for LDN, as your prescriber already does, remains the relevant safety check either way.

Dose separation: is a specific interval needed?

No. Because creatine and LDN do not share an absorption pathway, receptor, or metabolic enzyme, there is no pharmacological reason to separate the two doses by a set number of hours. LDN is typically taken at night, timed to align with the body's overnight rebound in opioid receptor activity. Creatine is usually taken with a meal or around exercise. Most people already separate them by habit rather than necessity, and that pattern is fine.

If you experience mild nausea in the first week or two of starting LDN, taking creatine earlier in the day may reduce overall stomach load at bedtime. That is a comfort adjustment, not a safety requirement.

Who should be more cautious

People with reduced kidney function. Creatine's effect on healthy kidneys is well described, but data specifically in people with chronic kidney disease are limited. The National Kidney Foundation does not describe a blanket prohibition but advises individualized caution for people with existing kidney disease considering creatine. Anyone with an eGFR below the normal range should discuss creatine use with the clinician managing their kidney disease before starting or continuing it, separate from any LDN question.

People taking other drugs that affect the kidneys. NSAIDs, certain antibiotics, and some other medications can independently affect kidney function or lab readings. Adding creatine on top of LDN plus a nephrotoxic medication makes lab interpretation harder, and cystatin C becomes more useful in that situation.

People starting a creatine loading phase. Higher loading doses (commonly cited around 20 g/day for several days, though protocols vary) produce a sharper, more noticeable creatinine rise than steady maintenance dosing. If you are about to start LDN and want baseline labs to be interpretable, it is reasonable to skip a loading phase and start at a standard maintenance dose instead.

What to tell your prescriber

A short, specific statement helps: "I take creatine monohydrate, roughly [X] grams per day. My serum creatinine may run higher than expected because of that. Can we check cystatin C as well, or instead, if kidney function is part of what we're monitoring for LDN?" This flags the confounder before it becomes a misread lab result and protects against an unnecessary pause in an LDN regimen that may be working.

If you're already taking both

This article is not a reason to stop either substance abruptly. If your labs have been stable and no kidney concern has been raised, the combination has likely been fine. At your next visit, mention the creatine use and ask whether a cystatin C check would be useful going forward.

If a creatinine value was flagged in the past while you were taking creatine, it is worth revisiting that result with your prescriber, ideally with a cystatin C measurement added, rather than assuming it reflected a kidney problem. A stable, mildly elevated creatinine alongside a normal cystatin C is consistent with a creatine effect rather than declining kidney function, though this interpretation should come from your own clinician reviewing your actual labs and history, not from this article.

When to seek urgent care

Creatine and LDN together are not expected to cause an acute medical emergency based on current evidence. Seek urgent medical attention regardless of supplement use if you develop signs of possible liver injury (yellowing of the skin or eyes, dark urine, severe abdominal pain, unusual fatigue) or signs of significant kidney problems (marked decrease in urination, swelling, confusion). These symptoms warrant evaluation whether or not creatine or LDN is a plausible cause.

A note on sources used in this draft: the original version of this article cited specific PubMed identifiers and a direct quotation attributed to a named researcher. Those identifiers could not be independently verified against the underlying papers for this rewrite, and the quotation could not be confirmed against a checkable source, so both have been removed or converted to general, unattributed statements pending verification by a qualified reviewer with access to the primary literature. Claims that previously carried a precise number (for example, an exact percentage rise in creatinine, or an exact patient count from a retrospective study) have been described qualitatively instead, and a clinician or medical librarian should confirm the specific figures before they are restored to the page.